Botanix Pharmaceuticals Limited (ASX:BOT) has responsibly accomplished a novel drug meeting with the US Food and Drug Administration department of Infectious Diseases.
The meeting evaluated the prospective of starting out a clinical development of the BOT’s antimicrobial drug BTX 1801 for blocking surgical site infections in the US.
The meeting also aided the company to obtain feedback from the FDA on the plan of BTX 1801 drug development.
It should be noted that in April 2020, BTX 1801 was given a Qualified Infectious Disease Product (QIDP) label. Any product with QIDP eminence gets next five years of regulatory superiority.
Botanix’s BTX 1801 is an artificial cannabidiol gel that is made to reduce post-surgical infections.
Meanwhile, the BOT stock was trading at $0.105 with a market capitalistaion of $102.13 million at 03:02 PM AEDT.